ForPatients
by Roche

Alzheimer's Disease (AD)

A Study of Gantenerumab in Participants With Mild Alzheimer Disease

Trial Status	Trial Runs In	Trial Identifier
Completed	22 Countries	NCT02051608 2013-003390-95 WN28745

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Part 1 is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab in participants with mild Alzheimer disease. Participants will be randomized to receive either gantenerumab subcutaneously every 4 weeks or placebo subcutaneously every 4 weeks. Approved Alzheimer medication is allowed if on stable dose for 3 months prior to screening. Part 2 is an open-label extension (OLE). A positron emission tomography (PET) imaging substudy will be conducted within the main study. Eligible participants who provide separate informed consent will undergo PET imaging scans using the radioligand florbetapir as a pharmacodynamic measure of changes in brain amyloid load over time.

Hoffmann-La Roche	Phase 3
Sponsor	Phase

NCT02051608 2013-003390-95 WN28745
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=50 Years & <= 90 Years	No